For older patients with rheumatoid arthritis (RA), there is considerable variation in time to receipt of first biologic disease-modifying antirheumatic drug (DMARD) after prescription of the first conventional synthetic (cs) DMARD.
Researchers assessed the most recent safety data of synthetic and biologic disease-modifying antirheumatic drugs to inform the 2019 update of the European League Against Rheumatism recommendations for the management of rheumatoid arthritis.
This study evaluated the frequency of achieving inactive disease in children with JIA treated solely with methotrexate and identified a model for patients with a lesser likelihood of reaching inactive disease with methotrexate.
Disease activity in patients with rheumatoid arthritis and access to bDMARD care varies across countries worldwide.
PROMIS measures can detect changes in symptoms of global health, pain, sleep, fatigue, and emotional health in patients with rheumatoid arthritis who are initiating DMARD therapy.
Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.
Petros Efthimiou, MD, a rheumatologist at NYU Langone Health, discusses how clinicians should approach prescribing potentially teratogenic drugs in pregnancy.
The ACR encourages healthcare providers to incorporate biosimilar drugs into treatment plans of patients with rheumatic diseases.
They similarities and differences of anti-TNF drug function in RA and SpA are discussed in an expert interview.
The safety of leflunomide use for rheumatoid arthritis during pregnancy was examined in a prospective study.
